title: Transarterial Chemoembolization of Liver Metastases from Uveal Melanoma Using Irinotecan-Loaded Beads: Treatment Response and Complications.
abstract: OBJECTIVE
  The purpose of this study was to evaluate treatment response and complications of transarterial chemoembolization using drug-eluting beads loaded with irinotecan (DEBIRI) in patients with liver metastases from uveal melanoma (UM).
  
  
  METHODS
  Patients treated with DEBIRI (n = 14) were retrospectively analyzed regarding overall survival, compared to patients (n = 14) treated with intravenous dacarbazine (DTIC). Median overall survival was calculated from time of diagnosis of metastatic disease (OS1) and start of treatment (OS2). Radiological response for DEBIRI was assessed according to RECIST 1.1 on contrast-enhanced computed tomography (CT), obtained 1.5 months (range 1.2-3.7) post treatment. Major complications of DEBIRI were defined according to the Society of Interventional Radiology classification for complications by outcome.
  
  
  RESULTS
  In the DEBIRI group, OS1 was 14.8 months (range 3.9-47.5), and OS2 was 9.4 months (range 1.7-39). Further, 11/13 (84.6%) of these patients had progressive disease on first follow-up CT and new lesions were seen in nine. There were 12 major complications in nine patients, possibly including one case of mortality due to disseminated intravascular coagulation (DIC).
  
  
  CONCLUSIONS
  For patients with liver metastases from UM, the effect on overall survival of DEBIRI alone is questionable. Compared to previous reports, the response rate of DEBIRI was poor, with new liver lesions observed in the majority of patients. Major complications possibly included one case of DIC.
authors.affiliation: Department of Radiology and Nuclear Medicine, Oslo University Hospital, Postbox 4950, 0424, Oslo, Norway. u.carling@gmail.com.
authors.forename: Ulrik
authors.initials: U
authors.lastname: Carling
authors.affiliation: Department of Radiology and Nuclear Medicine, Oslo University Hospital, Postbox 4950, 0424, Oslo, Norway. edorenbe@ous-hf.no.
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Dorenberg
authors.affiliation: Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Postbox 4950, 0424, Oslo, Norway. svhaug@ous-hf.no.
authors.forename: Sven-Petter
authors.initials: SP
authors.lastname: Haugvik
authors.affiliation: Department of Ophthalmology, Oslo University Hospital, Postbox 4950, 0424, Oslo, Norway. UXEIDN@ous-hf.no.
authors.forename: Nils Andreas
authors.initials: NA
authors.lastname: Eide
authors.affiliation: Department of Radiology and Nuclear Medicine, Oslo University Hospital, Postbox 4950, 0424, Oslo, Norway. DAGTB@ous-hf.no.
authors.forename: Dag Tallak
authors.initials: DT
authors.lastname: Berntzen
authors.affiliation: The Intervention Centre, Oslo University Hospital, Postbox 4950, 0424, Oslo, Norway. bjoedw@ous-hf.no.
authors.forename: Bjørn
authors.initials: B
authors.lastname: Edwin
authors.affiliation: Department of Oncology, Oslo University Hospital, Postbox 4950, 0424, Oslo, Norway. svedue@ous-hf.no.
authors.forename: Svein
authors.initials: S
authors.lastname: Dueland
authors.affiliation: Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Postbox 4950, 0424, Oslo, Norway. brosok@ous-hf.no.
authors.forename: Bård
authors.initials: B
authors.lastname: Røsok
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects / Q000379:methods*; D003287:Contrast Media; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008099:Liver / Q000000981:diagnostic imaging; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary* / Q000628:therapy*; D008297:Male; D008545:Melanoma / Q000473:pathology*; D008875:Middle Aged; D011856:Radiographic Image Enhancement; D012189:Retrospective Studies; D013812:Therapeutics; D014057:Tomography, X-Ray Computed; D014604:Uveal Neoplasms / Q000473:pathology*; D055815:Young Adult; D000098943:Uveal Melanoma
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D003287:Contrast Media; D000077146:Irinotecan; D002166:Camptothecin
keywords: DEBIRI; Drug-eluting beads; Irinotecan; Liver metastases; Transarterial chemoembolization; Uveal melanoma